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Natural killer (NK) cells are central components of the innate immunity. In murine models, it has been shown that NK cells
can control both local tumor growth and metastasis due to their ability to exert direct cellular cytotoxicity without prior
sensitization and to secrete immunostimulatory cytokines like IFN-γ. The latter participates in cancer elimination by inhibiting
cellular proliferation and angiogenesis,promoting apoptosis, and stimulating the adaptive immune system, and it is instrumental
for enhancing Ag processing and presentation. Nevertheless, NK cells display impaired functionality and capability to inﬁltrate
tumors in cancer patients. Also, NK cells are feasible targets of stimulation to participate in immunotherapeutic approaches like
antibody-based strategies and adoptive cell transfer. Thus, multiple attempts currently aim to manipulate NK for utilizationin the
immunotherapy of cancer.
1.Introduction
NK cells are eﬀector lymphocytes of the innate immune
system that control several types of tumors by limiting their
growth and dissemination [1]. In vitro studies using cells
from humans and several other mammalian species, as well
as in vivo studies in mice and rats, have long provided
evidence that tumor cells are recognized as NK cell targets
[2]. There are numerous studies in mice supporting the
notion that NK cells are involved in the elimination of
tumorcells.Theinvivoanalysesreliedonantibody-mediated
depletion of NK cells in mice, targeting either NK1.1 or
the glycolipidasialo-GM1 [3–5]. However, NK cell depletion
with antibodies to NK1.1 may also aﬀect populations of
invariant natural killer T cells and other NK1.1+ T-cell
populations. The selectivity of NK cell depletion with asialo-
GM1 antibodies (Abs) has also been hampered by the
expression of asialo-GM1 by several cell types including
myeloid cells, epithelial cells, and T-cell subsets. Caution
is therefore required when interpreting studies based upon
Ab depletion because of the lack of speciﬁcity of Ab
treatment against NK populations. Nevertheless, many other
independent studies advocate a role for NK cells in the
control of tumor development in mice. Particularly, mouse
NK cells are involved in the in vivo rejection of several
transplanted tumors, in a manner dependent upon the
presence or absence of NK cell receptor ligands expressed
by the tumor [6]. More informative studies regarding tumor
immunosurveillance are the experiments addressing the
control of newly arising tumors. In this respect Schreiber’s
group demonstrated that frequencies of spontaneously aris-
ing tumors or induced by methylcholantrene (MCA) were
higher in mice deﬁcient for key eﬀe c t o rm o l e c u l e so fN K
cells or the respective receptors [7, 8]. Nevertheless, in a
further study from the same group, it was shown that
although NK cells are important in the early elimination of
MCA-induced tumors, control of the “dormant” tumor state
depends mainly on adaptive immunity [9]. Other studies
provided evidence that NK cells can recognize and eliminate
aberrant cells. The lack of MHC class I expression [10]o r
the upregulation of NKG2D ligands [11, 12]c a nr e n d e r
tumor cells susceptible to NK cell-mediated lysis. In some of2 Journal of Biomedicine and Biotechnology
these experimental models, NK cell-mediated elimination of
tumor cells induced the subsequent development of tumor-
speciﬁc T-cell responses to the parental tumor cells [11, 13]
as a bridge between innate and adaptive immune responses
[14]. A role for NK cells in tumor immunosurveillance
has also been implicated in controlling the growth of B-
cell lymphomas that spontaneously arise in mice lacking
both perforin and β2-microglobulin [15]. Moreover, the
blockingofNKcellMHCclass-I-speciﬁcinhibitoryreceptors
increases NK cell eﬀector function against tumor cells in
mice [16]. In addition to their endogenous protective role in
tumor models, NK cells are also mediators of the antitumor
eﬀects of several recombinant cytokines, such as IL-2, IL-
12, IL-18, and IL-21 [6]. So far, these studies in vitro and
in animal models show the role of NK cells in cancer
immunosurveillance.
Clinicaland experimental evidencedemonstrate thatthis
important role of NK cells holds true in humans. Although
the paucity of NK cell-selective deﬁciencies has limited the
characterization of NK cell biological function in vivo in
general and in antitumor immunosurveillance in particular
[17], there is an 11-year follow-up epidemiologic survey
which has shown that the extent of NK cell activity in
peripheral blood is associated with cancer risk in adults:
low NK cell activity is associated with increased cancer risk
[18]. Furthermore, intratumoral NK cell studies have been
hampered because of the low numbers of these cells and the
diﬃculty to obtain them from tumor samples. However, in
the last few years, novel studies have revealed the phenotypic
status and functionality of NK cells in tumor site and also in
peripheral blood (PB) of cancer patients. First studies about
tumor immune inﬁltration have shown that the presence of
NK cells represents a positive prognostic marker in diﬀerent
carcinomas [19–21]. Further studies in established human
tumors showed that there are often only a few inﬁltrating
NK cells which are unlikely to greatly contribute to the
elimination of tumor cells [22, 23]. It has been suggested
that despite of low NK cell numbers in tumors, due to
their ineﬃcient homing into malignant tissues, this situa-
tion may be overcome by cytokine-mediated activation in
immunotherapeutical regimens [24]. In this respect, all this
evidence about NK importance in tumor immune control
enhances the appeal of NK cell-based immunotherapeutic
approaches. For instance, the beneﬁcial role of NK cells in
controlling human malignancies stems from clinical studies
ofleukemiapatientswho receivedalloreactive NKcellsin the
course of allogeneic hematopoietic stem cell transplantation
[25, 26]. Likewise, several studies have established the
importance ofFc-FcγRinteractions forthe in vivo antitumor
eﬀects of certain monoclonal antibodies [27–30]. In the
present work we will revise key aspects of NK cells role
from molecular and cellular characteristics to therapeutic
applications in cancer patients.
2.NK Cellsin CancerPatients
2.1. NK Cells Tumor Inﬁltration. Primary tumor growth is
a complex process, involving many interactions between
the tumors and surrounding tissue. A developing tumor
inﬂuences and is inﬂuenced by its stroma, initiates angio-
genesis, and interacts with both the adaptive and innate
immune systems. The clinicopathological signiﬁcance of the
tumor-inﬁltrating lymphocytes (TILs) in various human
cancers has been an issue of great interest. CD8+ cytotoxic
T cells (CTL) and NK cells are the most likely eﬀectors
for an eﬀective antitumor immunity [31]. Several studies
have shown that the inﬁltration of lymphocytes signiﬁcantly
correlates with a prolonged survival time of patients, at least
in certain types of cancer [32–34]. Typically, NK cells are
not found in large numbers in advanced human neoplasms,
indicating that they do not normally home eﬃciently to
malignant tissues. For instance, a low prevalence of gastric
andcolorectal(CRC)tumor-inﬁltratingCD56+ cellsinlivers
with multiple metastases was detected, whereas in cases with
solitary metastases ahigherdegreeoflymphocyteinﬁltration
was observed. Moreover, the percentage of intrahepatic NK
(CD56+) cells was also decreased in patients with metastases
compared to those without, being almost twice lower than
CD8+ and CD4+.T h i ss u g g e s t st h a tl o wN Kc e l ln u m b e r
could be a reason for the escape of metastatic cells from the
mechanisms of liver immune control [35]. In human nons-
mall cell lung cancers (NSCLC) NK cells percentage within
CD45+ mononuclear cells (MCs) isolated from lung tumors
was consistently lower than in MC from the PB counterpart
and was comparable to that in MC from peritumoral lung
tissue. With regard to their localization, NK cells were found
in tumor stroma, whereas they were not in direct contact
with cancer cells [36]. Another study in NSCLC showed that
NK cell inﬁltration was strikingly heterogenous. Malignant
and nonmalignant tissue areas in NSCLC were selectively
inﬁltrated by certain immune cell types with NK cells being
displaced from the tumor tissue and displaying low cytotoxic
activity[23].Inanotherstudy,theCD56+/CD16+ cellratioin
renal cell carcinoma microenvironment was found generally
lower than 1, suggesting that a predominant number of
CD16+ cells were CD56− macrophages, and a low NK cell
inﬁltration [37].
2.2. Tumor-Associated NK Cell Phenotype. The limited num-
berofNKcellsinﬁltrating tumorshashamperedmoreexten-
sive ex vivoanalyses of such tumor-associated cells. However,
novel studies of tumor-associated NK cells demonstrated
a striking phenotype, supporting the notion that tumor-
induced alterations of activating NK cell receptor expression
may hamper immune surveillance and promote tumor
progression. In this sense,severalauthorsstudiedthebalance
between inhibitory and activating receptors of NK cells that
inﬁltrate tumors, observing in some cases downregulation
of activating receptors and in others, overexpression of
inhibitory ones. In a study which analyzed the receptor
repertoire and functional integrity of NK cells in peritoneal
eﬀusions from patients with ovarian carcinoma, tumor-
associated NK cells expressed reduced levels of the activating
DNAM-1, 2B4, and CD16 receptors and were hyporespon-
sive to HLA class I-deﬁcient K562 cells and to coactivation
via DNAM-1 and 2B4, relative to autologous peripheral
blood NK cells. Moreover, tumor-associated NK cells wereJournal of Biomedicine and Biotechnology 3
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Figure 1: NK cell abnormalities in cancer patients. A defective immunity secondary to tumor development has been well established
in diﬀerent types of cancer. The imbalance of immune status is inclined to immunosuppression in cancer patients which results in a
concomitant tendency to tumor immune evasion. Such immunosuppression is characterized by a decrease in NK cell numbers in PB and a
decreased intumorinﬁltrateascompared to normaltissue. Moreover, in manytypes ofcancer analtered phenotypewhich presents defective
expression of activating receptors and overexpression of inhibitory receptors is observed.
also refractory to CD16 receptor stimulation, resulting
in diminished Ab-dependent cellular cytotoxicity (ADCC)
against autologous tumor cells [38]. In another study,
tongue cancer intraepithelial NK cells expressed NKG2A, an
inhibitory receptor that recognizes HLA-E, more frequently
than those in the stroma or in lichen planus. Collectively, the
intraepithelialCD8+ TcellsandNKcellswerephenotypically
inactivated, whereas stromal counterparts were phenotypi-
cally just as active as those in lichen planus, suggesting the
suppressed state of the intraepithelial NK cells [39]. Carrega
and coworkers described both relevant molecule expression
and function of NK cells inﬁltrating NSCLC in comparison
with autologous NK cells isolated from either peritumoral
normal lung tissues or PB. The CD56brightCD16− NK cell
subset was highly enriched in tumor inﬁltrate and displayed
activation markers, including NKp44, CD69, and HLA-DR.
Remarkably, the cytolytic potential of NK cells isolated from
cancer tissues was lower than that of NK cells from PB
or normal lung tissue, whereas no diﬀerence was observed
regarding their capability of producing cytokines [36]. In
acute myeloid leukemia (AML) it was demonstrated that
CD137 ligand (CD137L) was expressed on leukemic cells
and interacts with CD137 on activated NK cells. Bidi-
rectional signaling following CD137-CD137L interaction
induced the release of the immunomodulatory cytokines
IL-10 and TNF by AML cells and directly diminished
granule mobilization, cytotoxicity, and IFN-γ production
by human NK cells, demonstrating an immune evasion
of AML cells by impairing NK-cell tumor surveillance
[40].
2.3. Peripheral Blood NK Phenotype. Not only did NK inﬁl-
trating tumor cells show a diﬀerent phenotype or reduced
cytotoxicity, but in some kind of cancers this was also
observed in NK cells from PB. In a study in metastatic
melanoma (MM) patients, NK cells presented decreased
activity and IFN-γ production and also had a redistribution
of NK cell subsets. It was observed an increase in non-
cytotoxic CD16dimCD56bright and a reduction in cytotoxic
CD16brightCD56dim NK cell subsets. Moreover, there was a
decreased CD161 and NKG2D activating receptors and an
overexpressed CD158a inhibitory NK cell receptor, which
correlated to lower NK cell cytotoxicity [41]. These results
are in agreement with another study in MM where a
signiﬁcantly lower percentage of NK cells expressed CD16,
NKp30, and NKp46 activating receptors as compared to
healthy donors. In addition, despite the importance of
NKG2D in recognizing MM cells, no substantial diﬀerences
were observed between stage IV MM patients and healthy
donors [41]. These observations imply that down-regulated
NK litic receptor expression in MM patients may aﬀect NK
cells ability to recognize and eliminate tumor cells [42].
Likewise, the frequency of NK cells expressing the activating
receptors NKp30,NKp44,NKp46,NKG2D,and NKG2Cwas
signiﬁcantly decreased in AML patients compared to the
NK cells of normal controls [43]. Although the molecular
mechanisms responsible for the reduced receptor expression
in PB NK cells remains elusive, elevated serum levels of
soluble NK cell receptor ligands shed by tumor cells have
beenassociated with downregulationoftheNKcellreceptors
and might contribute to the decreased levels of NK cell
activity [44].
In this section, we cited works which showed some
impaired NK cells characteristics in cancer patients which
determine their inability to eliminate tumor cells (depicted
in Figure 1). On the other hand, it is a fact that NK4 Journal of Biomedicine and Biotechnology
cells are potentially active against tumor cells and it is
feasible to manipulate them to restore and/or improve
theirantitumoralactivity.NKcell-basedimmunotherapeutic
approaches will be reviewed in next section.
3.NK CellTherapy
3.1. Monoclonal Antibodies. Many mechanisms have been
proposed to explain the clinical antitumor activity of uncon-
jugated tumor antigen-speciﬁc monoclonal Abs (MAbs).
The ability of some MAbs to disrupt signalling pathways
involved in the maintenance of the malignant phenotype
has received widespread attention. In addition, Abs exhibit
various immunomodulatory properties and, by directly acti-
vating or inhibiting molecules of the immune system, they
can promote the induction of antitumor immune responses.
However, this ability has been less studied. In this section,
we will describe NK cell-mediated ADCC mechanism and
discuss the potential use of MAbs to manipulate the host
immune response to tumors.
3.2.Antibody-Dependent Cellular Cytotoxicity. Abs are linked
to immune eﬀector functions by the Fc fragment, which is
capable of initiating ADCC when binding to Fc receptors,
specially FcγRIII (CD16) on NK cells, which initiates a
sequence of cellular events culminating in the release of
cytotoxicgranzyme-containing granules andINF-γ secretion
[45–47]. Several studies have established the importance of
Fc-FcγR interactions for the antitumor eﬀects of certain
MAbs in murine models and clinical trials. A seminal paper
showed thatthe antitumoractivities of theanti-HER-2 MAb,
Trastuzumab, and the anti-CD20 MAb, Rituximab, were
lower in FcγR-deﬁcient mice than in wild-type mice [48].
The role of FcγR in the antitumor response has been further
supported by the ﬁnding that polymorphisms in the gene
encoding FcγRIII, which lead to higher binding of Ab to
FcγRIII,areassociated withhighresponse ratestoRituximab
in patients with follicular non-Hodgkin’s lymphoma [27]. A
separatestudythatcomparedclinicalresponses toRituximab
in patients with follicular lymphoma suggested that both
FcγRIIIandFcγRIIBhavearoleintheresponsetoRituximab
[28]. More recent ﬁndings show that polymorphisms in
genes encoding FcγRs are associated with clinical responses
to other Abs, including Trastuzumab [29] and the anti-
EGFR MAb, Cetuximab [30]. Patients with breast cancer
who responded to Trastuzumab with complete or partial
remission have been found to have a higher capability to
mediate in vitro ADCC in response to Trastuzumab than
patients whose tumors failed to respond to therapy [29].
ADCC enhancement through Fc domain modiﬁcation has
shown promise in the development of next generation
MAbs. For example, a CD19-speciﬁc MAb with increased
FcγRIIIA binding aﬃnity mediated signiﬁcantly increased
ADCC compared to its parental MAb and Rituximab [49].
The in vivo infusion of this high aﬃnity MAb eﬃciently
cleared malignant B cells in cynomolgus macaques (Macaca
fascicularis)[ 50].
3.3. Potentiating ADCC. In previous reports, we and others
provedthatNKcellsproduceCetuximab-mediatedADCCof
metastatic CRC (mCRC) and that this activity is not aﬀected
by the mutational status of the downstream molecule K-RAS
[51, 52]. This eﬀect is expected because NK cells recognize
the surface-bound Abs and are able to kill tumor cells
independentlyoftheEGFRpathwayactivation.Nevertheless,
itremains tobeanswered why inmCRCpatientswith K-RAS
mutated status Cetuximab-mediated ADCC does not induce
clinical remissions. As we discussed, one of the possibilities
is the low proportion of NK cells inﬁltrating CRC tumors
[53] and the low functional capacity of these cells observed
in cancer patients [54, 55]. Therefore, if it were possible to
enhance the activity of NK cells, the eﬃcacy of treatment
with Cetuximab could be increased. The anti-VEGF-A
MAb, Bevacizumab, is also active in mCRC, regardless of
the K-RAS mutation status; nevertheless, it needs to be
administered in combination with a cytotoxic agent [56].
Regarding ADCC enhancer molecules, Lenalidomide, an
analog of thalidomide, is able to potentiate ADCC in vitro.
Lenalidomide enhanced NK cell and monocyte-mediated
ADCC of Rituximab against a variety of hematological
cell lines in vitro [57]. Lenalidomide also enhanced NK
cell-mediated lysis of Cetuximab and Trastuzumab-coated
CRC and breast cancer cells, respectively. The ability of
lenalidomide to enhance Cetuximab-mediated ADCC of
CRC cells was not aﬀected by the K-RAS mutational status
[58].Becausepanitumumab,anIgG2aanti-EGFRMAb,does
not eﬀectively interact with Fcγ receptors on the NK cell
surface, it was unable to initiate ADCC and, as expected,
lenalidomide had no eﬀect because its activity is reliant
on the augmentation of NK cell signaling downstream
of FcγR. An early clinical study exploring this eﬀect of
lenalidomide in K-RAS mutant tumors has been initiated
[59].
As explained previously, many studies demonstrated
the impairment of NK cell activity in cancer patients. In
these cases, cytokines could restore and potentiate NK cell-
mediated ADCC. The works cited below explain how these
treatments work when patients present NK cell dysfunction.
Cetuximab was tested in various in vitro studies in patients
with esophageal squamous cell carcinoma (ESCC) to eval-
uate the possibility of treatment. Authors ﬁrst performed
detailed analysis of ADCC mediated by Cetuximab against
ESCC cell lines with various levels of EGFR. The activities
of Cetuximab-mediated ADCC by patients’ PBMC were
impaired in comparison with those by healthy donors’
PBMC. Moreover, the inhibition of transforming growth
factor (TGF)-β could enhance Cetuximab-mediated ADCC
against TGF-β-producing ESCC [60]. In other work, down-
regulated CD16 and upregulated CD56 molecules on NK
cells were observed in ESCC patients, resulting in NK cell
dysfunction. After patients received curative resections of
ESCC,the downregulated CD16and upregulatedCD56were
signiﬁcantly restored to the levels of healthy donors. TGF-
β1 was found to partially contribute to downregulation of
CD16 on NK cells [61]. Watanabe and coworkers evaluated
whether IL-21 could improve the impairment of ADCC
in patients with ESCC as IL-21 was reported to have theJournal of Biomedicine and Biotechnology 5
ability to activate NK cells. Trastuzumab- and Cetuximab-
mediated ADCC of PBMC or of enriched NK cells was
enhanced by the addition of IL-21 in a dose-dependent
manner and the levels of ADCC enhanced by IL-21 in
patients were high enough in comparison with those in
healthy donors, paralleling the upregulation of CD247 on
NK cells [55]. As in the previous example, NK cell response
to Cetuximab-coated tumor cells could be enhanced by the
administration of NK cell stimulatory cytokines IL-2, IL-
12, or IL-21 and resulted in higher IFN-γ production than
was observed with either agent alone. NK cell-derived IFN-γ
signiﬁcantly enhanced monocyte ADCCagainst Cetuximab-
coated tumor cells. Costimulated NK cells also secreted ele-
vated levels of chemokines (IL-8, macrophage inﬂammatory
protein-1a, and RANTES) that could direct the migration of
naive and activated T cells. Furthermore, administration of
IL-21 enhanced the eﬀects of Cetuximab in a murine tumor
model [62]. In other experimental study, it was analyzed the
correlationbetweenEGFRexpressioninlungcancercelllines
and the ADCC activity of Cetuximab as well as the inﬂuence
of IL-2 and chemotherapy on ADCC activity. A logarithmic
correlation was observed between the number of EGFRs and
ADCC activity. In addition, NK cell-mediated ADCC was
enhanced by IL-2 and such cells were also less susceptible to
immunosuppression by chemotherapy than in lung cancer
patients [63]. The antitumor eﬀect and mechanism of action
of Cetuximab using EGFR high-expressing and EGFR low-
expressing gastric cancer cell lines without gene ampliﬁca-
tion was investigated. Cetuximab showed neither signiﬁcant
growth inhibition nor induction of apoptosis in either cell
line in vitro, and only slightly inhibited ligand-induced
phosphorylation of protein kinase B and extracellular signal-
regulated kinase. In contrast, Cetuximab signiﬁcantly inhib-
ited subcutaneousand intraperitoneal tumorgrowth in nude
mice. This antitumor activity was signiﬁcantly enhanced
and diminished by treatment with IL-2 and antiasialo GM1
Ab, respectively [64]. In that study, HER-2/neu-expressing
gastric cancer cells could be killed by Herceptin, the anti-
HER-2/neu MAb. Herceptin-mediated ADCC correlated
with the degree of HER-2/neu expression on the gastric
cancer cells. However, the Herceptin-mediated ADCC was
signiﬁcantly impaired in PBMC from advanced disease
patients compared with that in early disease or healthy
individuals. Moreover, NK cells puriﬁed from patients with
advanced disease indicated less Herceptin-mediated ADCC
in comparison with that from healthy donors, whereas
monocytes puriﬁed from the patients showed an almost
equal amount of Herceptin-mediated ADCC in comparison
with that from healthy individuals, indicating that NK
cell dysfunction contributed to the impaired Herceptin-
mediated ADCC in gastric cancer patients. Furthermore, the
NK-cell dysfunction on Herceptin-mediated ADCC corre-
lated with the downregulation of CD16 expression in the
patients, and IL-2 ex vivo treatment of NK cells could restore
the impairment of Herceptin-mediated ADCC, concomitant
to the normalization of the expression of CD16 molecules
[65]. In our laboratory, we performed in vitro studies
on human triple negative breast cancer (TNBC) K-RAS-
mutated cell lines. We found that EGFR-expressing TNBC
could be killed by Cetuximab-mediated ADCC at clinically
achievable concentrations. Furthermore, IL-15 could replace
IL-2 in most of its immunologic activities, stimulating NK
cells ability to produceIFN-γ, paralleling the upregulation of
activatingreceptors[66].TheseresultsshowthatCetuximab-
mediatedNKcellactivitycanbesigniﬁcantlyenhancedinthe
presence of NK cell stimulatory cytokines.
3.4. Adoptive Cell Transfer. Adoptive cell transfer (ACT)
therapy can be considered as a strategy aimed at replacing,
repairing, or enhancing the biological function of the
immune system by means of autologous or allogeneic cells.
ACT therapy may include (i) removal or enrichment of
various cell populations; (ii) expansion of hematopoietic cell
subsets; (iii) activation of lymphocytes for immunotherapy;
(iv) genetic modiﬁcation of lymphoid cells, when these cells
are intended to engraft transiently in the recipient and/or be
used in the treatment of cancer. This section contains exten-
sive considerations on clinical and laboratory experience in
immunologic targeting of malignant cell populations, and
how lasting curative responses can be eﬀectively generated.
As we will discuss, the use of lymphocytes and/or NK cells
as a strategic weapon in preventing or curing the neoplastic
relapse after surgery/chemotherapy has been applied to the
treatment of hematological malignancies and solid tumors.
NK cells represent a promising cell type to uti-
lize for eﬀective adoptive immunotherapy. Transfer of
tumor-inﬁltrating lymphocytes has shown some remarkable
responses in patients with advanced MM [67]. Nevertheless,
problems with deriving suﬃcient numbers of these cells
from patients, downregulation of MHC class I ligands and
costimulatory ligands on tumor cells, combined with the
lack of persistence of transferred cells have precluded broad
utilization of these cells for the treatment of cancer patients.
Thetransfer ofotherimmunesubsets,suchasNKcellswhich
do not require prior sensitization to respond to target cells
and can potently induce a cytolytic response, represents a
good alternate or auxiliary cell type for immunotherapy.
3.5. Ex Vivo Expansion. One of the main hurdles involved
in developing adoptive transfer of immune cells has been to
deﬁne good manufacturing procedures (GMPs) compliant
methods to isolate deﬁned subsets with the number of cells
required thatguarantee the safety ofthe injectionto patients.
In this respect, clinical-grade production of NK cells has
proven eﬃcient [68], and large-scale expansion method has
been possible for human NK cells [69], using a cytokine-
based culture system for ex vivo expansion of NK cells
from hematopoietic progenitor cells from umbilical cord
blood. Systematic reﬁnement of this two-step system using
a novel clinical-grade medium resulted in a therapeutically
applicable cell culture protocol. Nevertheless, improved
technologies for NK cells expansion lately have been tested.
NK cells from myeloma patients expanded in a bioreactor
displayed signiﬁcantly higher cytotoxic capacity. It was
possible to partially attribute this to a higher expression level
of NKp44 compared with NK cells expanded in ﬂasks [70].
These resultsdemonstratethatlargeamounts ofhighlyactive6 Journal of Biomedicine and Biotechnology
NK cells for adoptive immunotherapy can be produced in
a closed, automated, large-scale bioreactor under feeder-free
current GMP conditions, facilitating clinical trials for the use
of these cells.
Even when the ﬁrst works were based on transplantation
of autologousex vivoexpanded cells, and in addition to what
weearlier discussedoncancerpatientsNKcellsdysfunctions,
it is now understood that the failure of autologous NK
therapy is partially due to the downregulation of NK cell
killing that occurs with recognition of self-class I MHC on
tumor cells [71–73], making allogeneic cell transfer more
attractive. During allogeneic hematopoietic stem cell trans-
plantation, NK cells have been implicated in the suppression
of Graft versus Host Disease (GVHD), the promotion of
bone marrow engraftment, and mediation of a Graft versus
Leukemia (GVL) eﬀect [74]. In the setting of allogeneic ACT
in leukemias, the results of NK cells activity depend on the
directionality of lysis [75, 76]. When the NK cells are donor-
derived and the recipient cells lack expression of the cognate
KIR ligand, the donor NK cell lysis of recipient target cells
can result in GVL and/or GVHD, depending on the tissue
origin of the NK cell target. However, if the target cell is of
donor origin, and the NK eﬀector cell is of recipient origin,
NK cell lysis can result in graft rejection. Recent studies have
demonstrated that NK cell eﬀector capacity is inﬂuenced
by class and quantity of inhibitory receptors for self-HLA-
Ba n dH L A - Cl i g a n d s[ 77, 78]. It has been estimated that
NK cell alloreactivity can be expected to occur in about
50% of unrelated donor transplants with one or more HLA
allele level mismatches. Velardi and coworkers announced
a new era in the exploitation of NK cells for cancer
immunotherapy with a pioneering study of hematopoietic
stem cell transplantation that stratiﬁed patients according
to KIR-ligand mismatch between donor cells and recipient
leukemic cells [74]. This reveals that alloreactive NK cells,
unrestrained by inhibitory signals from the recipient HLA
ligands, protects against disease relapse. This KIR-ligand
mismatch phenomenon has attracted researchers to study
it, and similar observations have since been made in
other trials of leukemia immunotherapy [79–81]. On the
other hand, further studies extended HLA match analysis
to the mechanisms involved in GVHD. In patients with
hematologic malignancies who received transplants from
unrelated donors, genotype analysis of six major HLA loci
identiﬁed 4 HLA-C and 6 HLADPB1 mismatch combina-
tions responsible for a decreased risk of relapse and severe
acuteGVHD.Donorselectionmadeinconsiderationofthese
resultsmightallowtheseparationofGVLfromacuteGVHD,
especiallyin HLA-DPB1mismatch combinations[82].These
ﬁndings might be crucial to elucidating the mechanism of
the decreased risk of relapse on the basis of HLA molecule
haplotype (Figure 2).
The eﬀectiveness of adoptive transfer of expanded NK
cells for the treatment of relapsed leukemia has been
demonstrated, and ongoing eﬀorts are designed to evaluate
this approach in the treatment of solid tumor malignancies
as well [83–85]. Despite this therapy has been proven safe
f orpa ti en tsa n df ea s i ble,m or eeﬀectivestrategies to augment
in vivo NK cell persistence and expansion are needed to
test the clinical beneﬁt of NK cells against solid tumors,
as literature supports the notion that there is a cell dose
response in ACT. In a phase II clinical trial in patients with
ovarian and breast cancer, the adoptive transfer of haplo-
identical NK cells after lymphodepleting chemotherapy was
associated with transient donor chimerism that was not
improved with the addition of low-dose total body irradi-
ation. Sustained in vivo NK cell expansion may be limited
by host rejection, competition with host lymphocytes or
suppression by recipient regulatory T cells (Treg) or myelo-
derived suppressor cells [86]. To provide a greater number
of NK cells with a diﬀerentiated activated phenotype for
adoptive immunotherapy, some authors described cytokine-
based methods useful for clinical-scale NK cell production.
A phase I clinical study evaluated the safety of donor lym-
phocyte infusions following allogeneic hematopoietic stem
cell transplantation to patients with progressive malignant
disease. This study reported the safety of ex vivo-expanded
NK and NK-like T cells with a feeder-free cGMP com-
patible expansion strategy administered to humans also in
combination with IL-2 [87]. Decot and coworkers described
an immunomagnetic technique consisting in CD3/CD19
depletion eﬀective to obtain highly T- and B-cell-depleted
NK cell-enriched product with GMP-compliant reagents.
IL-2 or IL-15 were equivalent to signiﬁcantly enhance NK
cell cytotoxicity after culture with MHC-class I negative
erythroleukemia cell line. Furthermore, they observed a
modiﬁcation in NK-cell receptor expression pattern with
upregulation of the activating receptor NKG2D, but also of
the inhibiting receptors KIR2DL1 and KIR2DL2 [88]. In
other work PBMC were cultured in serum-free medium and
IL-2for20days.Cellsintheculturewerealsostimulatedwith
anti-CD3 Ab (OKT3). Safety and feasibility of administering
ex vivo expanded NK and NK-like T-eﬀector cells as donor
lymphocytes infusion to ﬁve cancer patients after stem
cell transplantation was evaluated. Cell infusions, with or
without IL-2 injections, seemed to be safe as no GVHD
was observed. Not only do all these data support a role
of NK cell during ACT therapy, but results also link NK
cell recovery with a GVL rather than with a GVHD eﬀect,
as recipient’s NK cells have been shown to be the ﬁrst of
lymphoid lineage cells to reconstitute following allogeneic
transplantation, and adequate recovery of NK cell number
in the early posttransplant period has been associated with
improved relapse-free outcome [89].
These studies now provide the backdrop for the devel-
opment of therapies that enhance the therapeutic beneﬁt of
allogeneic transplantation while minimizing the risks and
toxicities associated with treatment (Figure 3).
3.6. Concluding Remarks. In recent years there have been
signiﬁcant advances in the discovery of the molecular
mechanisms that govern the reactivity of NK cells against
tumors. In this paper we have reviewed how the expression
and function of both inhibitory and activating NK receptors
are involved in the molecular regulation of innate immunity
in malignant settings.
NK cells are also potential tools for cancer therapy,
both due to cytotoxic ability enhanced by antibodies andJournal of Biomedicine and Biotechnology 7
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Figure 2: NK cell tumor immunity and alloimmunity after allogeneic ACT. Autologous NK cell killing is inhibited when self-class I MHC
on tumor cells is recognized. In allogeneic ACT, NK cell KIR-mismatch is implicated both in GVHD and in mediating of a GVL eﬀect.
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Figure 3: NK cell-based immunotherapies. Overview of current approaches being tested in clinical settings. (a) Infusion of tumor-speciﬁc
MAbs triggers an ADCC response. (b) ADCC can be potentiated with the coadministration of cytokines. (c) Autologous and (d) allogeneic
transfer of NK cells, which can be manipulated ex vivo with diﬀerent approaches.8 Journal of Biomedicine and Biotechnology
the possibility of ex vivo expansion and adoptive transfer.
Nevertheless therapeutical regimens need to be further
developed. Inasmuch as one scheme will not be suitable for
all malignancies, diﬀerent approaches are to be evaluated for
each particular case.
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